Can $AIKI Alkido Pharma Inc Stock Price Recover?
About the Alkido Pharma company
AIkido Pharma Inc is a cancer drug, small molecule biotechnology company.
Its main focus is on developing a diverse portfolio of anti-cancer drugs based on a small molecule design which the company believes holds the best future for next-gen therapeutics.
Recently, Alkido Pharma patented a number of different technologies through some top universities.
Its current drug portfolio can treat pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
Additionally, AIkido also focuses on treating multiple types of viral infections.
Its antiviral platform includes a large portfolio of drugs that inhibit replication of multiple viruses including Influenza virus and Covid-19 with different epitope.
AIkido also has lots of subsidiaries for developing different treatment drugs which includes,
- Nuta Technology Corp,
- Spherix Management Services, LLC (SMS),
- Spherix Delaware Merger Sub Inc, and
- NNPT as well as LLC and others.
The company is classified under the Biotechnology sector and has an address at One Rockefeller Plaza, 11th floor, New York, United States 10020.
Key people at AIkido Pharma Inc
It is important to know the people behind this pharmaceutical industry as success in the biology field depends on the people who operate it.
Robert J. Vander Zanden
Independent Chairman of the Board
Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Director
Robert Frederick Dudley
Recent decline in stock price
The Aikido Pharma Inc stock price fell by more than 6% on Friday, 21st January 2022 from $0.51 to $0.465, and has now fallen 7 days in-a-row.
During Friday trading, the stock suffered extreme volatility at 5.59% from a day low at $0.465, to a day high of $0.512.
The price has fallen most days in the past 2 weeks and is down by -19.87% in total during this period.
This is an early warning sign and the risk is more for the coming weeks as investors are selling shares despite an increase in volume of more than 47,000 shares.
Overall, 1.5 million shares were bought and sold for approximately $700.80 thousand according to recent statistical analysis.
The stock has broken the downtrend support and falling towards an oversold state reading from the RSI weekly chart.
A stronger fall rate over an extended period of time may indicate panic selling, but not because of any negative news from or about the company.
It is rather a pre-expectation of the future, but false breakouts may trigger stop losses and hence it may be wise, not to have a stop loss in place for this company’s shares during these volatile times.
According to one analyst, $0.4 will represent the new support at the bottom and realistically the share price doesn’t look like it would fall further as the company appears to hold good value for the future.
Two analysts give a 1 year price forecast for Aikido Pharma Inc with a median target of 1.94, with a high estimate of 2.5 and a low estimate of 1.34.
The median estimate represents a +270% approximate increase from the last price of 0.475.
The current consensus is to buy stock in Aikido Pharma Inc now as the stock is undervalued and has potential to double the capital invested.
Signals & Forecast
There are many technical analysis that provide little positive signals at this time.
The Aikido Pharma Inc stock holds sell signals from moving averages for both the long and short term which is a more negative forecast for the stock.
With an oversold signal with corrections up, there will be some resistance from the lines at $0.5 and $0.6.
A break of resistance above any of these levels will provide clear buy signals and so far it has fallen -24.31% from pivot point.
Further falls may occur until a new strong support is found. Furthermore, there is currently a slight sell signal from the 90 days Moving Average Convergence Divergence (MACD).
In technical terms, this is called panic selling and may be an early warning not to sell shares, but to hold them for a few more years to come.
In some cases, increasing volume on falling prices may be a good sign for bullish investors, but that is mainly in panic “sell-offs”.
Support, Risk & Stop-loss
There is little to no support from the volume accumulated on Friday and the stock may perform negatively during next week, but this should ease and there is more chance of a rebound.
This stock is considered as having low risk and high reward considering that it is already near an all-time low, and may move higher due to volatility and with a big gap in interval from the Bollinger Band this stock is considered to be a “Best Buy”.
During the last few weeks, the Aikido stock has good volatility and volume consistency with overall sell offs in the Nasdaq market for correction.
Aikido Pharma Inc is extremely oversold on RSI14 (23 days). Some stocks may drop much more before turning around, which makes this stock an amazing price to buy for a massive return in a year or so.
Once again, in my view,
I wouldn’t set up a stop loss after buying at these low prices, given moreover I’d be looking to buy and hold this for at least over the next 2 years.
Is Aikido Pharma Inc stock A Buy?
Aikido Pharma Inc, despite holding negative signals technically doesn’t look good, but fundamentally it is a good buy as holding a portfolio of drugs could cause breakthroughs with good data in pre-clinical studies.
I believe the Aikido share price will move up massively on one single good news in an upcoming press release.
Insider buying? This matters the most?
In the last 150 trades there were 6 million shares bought and 200 thousand shares sold. The last trade was some 175 days ago by Mr. Robert J who bought nearly 20 thousand shares.
The large amount of stocks bought compared to stocks that were sold might indicate that the insiders believe there is a massive upside potential.
I am willing to invest at this stage as this is the best price to buy and hold in my view.
The AIkido Pharma stock price is declining due to panic expectation which shouldn’t worry a long term investor who knows the ins and outs of their drugs portfolio.
Some of the analysis has been performed by deep learning algorithms.
Many investors might believe this is the right time to buy AIKI as it could be a good portfolio addition.
These predictions take several variables into account such as volume and price changes along with market news and similar stock performance in past history.
The future price of the stock is predicted at 2.25$ (350.3%) after 2023 according to one algorithm which makes it a hold and buy for at least one year from now.
This means that if you invested $10,000 now, your current investment may be worth around $35,000 come January 2023.
This also means that this stock is suited for bullish investors who are aiming for massive returns in a few years from now.
According to the present data analysis, AIkido Pharma’s shares and potentially other factors have been bearish for the past year due to lack of positive news updates despite stellar products.
Currently there is also a parallel trend where stocks in the Healthcare industry have been in decline over the last 12 months.
My analysis reveals that AIKI shares are a good investment for making money.
Since this share has reached an all-time low and the company is still aiming for good development, with insider buying, I think this stock is a prime buying opportunity.
If you don’t have much capital and want to try and scale a small pot of funds up massively – and in a relatively short space of time – you could try buying the shares in AIkido Pharma on the NASDAQ stock exchange.
Can $AIKI Alkido Pharma Inc Stock Price Recover?
You should weigh up the risk for yourself since nothing is guaranteed.
If you are interested in reading about stocks, TabStocks.com have many stock pick articles you can read for free.
If this information has been useful to you, kindly consider making a financial PayPal donation to support our work in continuing to provide you with free quality content.
We have taken reasonable steps to make sure that any information on this website is accurate at the time of publishing. Any opinions expressed are the opinions of the author only. The content on TabStocks.com is not recommendations to buy or sell. We do not give personal financial investment advice and the information on this website and via our email newsletters should not be taken as us giving any individual or organisation such advice directly or indirectly. You should do your own research and due diligence before trading or investing or speak to an independent qualified financial adviser. Do not rely upon the information on this website or via our newsletters when making an investment decision. No liability is accepted by the author, TabStocks.com or its Officers for any investment loss, or any other loss or detriment experienced by any individual for any investment decision, whether consequent to, or in any way related to the content on this website and/or information in emails from this website.